Press Release

VLP Therapeutics Receives Grant from Global Health Innovative Technology (GHIT) Fund to Develop New Vaccine for Dengue Fever

2016.10.05|

Gaithersburg, Md.-- (PR NEWS WIRE) — October 5, 2016 -- VLP Therapeutics, LLC. announced today that it has received a grant for approximately US$960,000 from the Global Health Innovative Technology

VLP Therapeutics Appoints Louis M. Weiner, M.D., Director of Georgetown Lombardi Comprehensive Cancer Center as Scientific Advisor

2016.03.15|

Gaithersburg, Md.— March 14, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents

VLP Therapeutics Announces Issuance of U.S. Composition of Matter Patent for i-α Virus Like Particle Platform Technology – Intellectual Property Estate Strengthens Malaria, Dengue and Zika Virus Disease Program –

2016.02.08|

Gaithersburg, Md.—February 8, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,249,191, Virus Like Particle

VLP Therapeutics to Present at 2015 Dasan Conference

2015.12.02|

VLP Therapeutics, LLC. (“VLP”) announced that its Chief Executive Officer, Dr. Wataru Akahata, was invited to speak at the 2015 Dasan Conference in Busan, Korea on Wednesday, December 2, 2015, at 3:00 p.m. Local Time. The event, which is hosted by the Korean Federation of Science and Technology Societies (KOFST) is titled “the Development of Novel Technology for the Preparedness of Emerging and Unknown Infectious Diseases”and take place at Saintmare, Busan, Korea.